Sign In
Buy DYN
$17.99
+0.750 (+4.35%)
At Close: Jun 03, 2026
Dyne Therapeutics Announces Key Leadership Appointments
06:31am, Tuesday, 03'rd Sep 2024
- Building Team to Prepare for Commercialization as Company Pursues Expedited Approval Pathways for DM1 and DMD Clinical Programs -
- Initiating Registrational Cohorts with Update on Path to Registration by Year-End 2024 - - Virtual Investor Event Today at 8:00 a.m. ET -
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
07:30am, Thursday, 29'th Aug 2024
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
05:10pm, Monday, 12'th Aug 2024
- Recent Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrated Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints -
Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why
09:51am, Monday, 29'th Jul 2024
Dyne Therapeutics (DYN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?
01:02pm, Thursday, 18'th Jul 2024
Does Dyne Therapeutics, Inc. (DYN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why
09:52am, Friday, 12'th Jul 2024
Dyne Therapeutics (DYN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed throu
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models -
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
07:30am, Thursday, 30'th May 2024
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peopl
WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peopl
Up 165% This Year Will Dyne Therapeutics Continue Its Stellar Run?
08:00am, Wednesday, 22'nd May 2024
Dyne Therapeutics stock (NASDAQ NASDAQ : DYN), a biotechnology company focused on advancing genetically driven muscle diseases therapeutics, saw a significant 28% rise on Monday, May 20. This move cam
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
08:39pm, Tuesday, 21'st May 2024
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
01:30pm, Tuesday, 21'st May 2024
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 20'th May 2024
WALTHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
